Maintenance Therapy for Multiple Myeloma Patients

Tuesday, Oct 19th
1:00 PM - 2:00 PM (ET)

 

Join us for a FREE one hour webinar! Learn about maintenance therapy: the principle behind its use, the effectiveness and safety of the drugs used, and the patients most likely to benefit.

 

 

Maintenance Therapy for Multiple Myeloma Patients

CELEBRATING 20 YEARS OF ARCHITECTURAL EXCELLENCE.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupt.
 

MMRF Patient Webinar:
Maintenance Therapy for Multiple Myeloma Patients


EVENT DETAILS


In multiple myeloma management, the goals of maintenance therapy are to maintain treatment response for as long as possible and to extend survival. A growing body of evidence supports the role of maintenance therapy after the completion of induction therapy or after transplantation. Currently, Revlimid is the only drug approved as maintenance therapy for myeloma patients following a stem cell transplant. However, because some patients are unable to tolerate Revlimid for an extended time, many other drugs are also being investigated as maintenance therapy.

EVENT FACULTY



OUR SPONSORS